Ad
Tuesday, 6 February 2018
Array melanoma drugs show significant survival vs Roche drug in study
(Reuters) - A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment